Screener
Alto Neuroscience ANRO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $263,762 | $176,484 |
| Prepaid expenses and other current assets | 5,364 | 1,234 |
| Total current assets | 269,126 | 177,718 |
| Restricted cash | 500 | 500 |
| Property and equipment, net | 2,234 | 1,872 |
| Operating right-of-use asset | 4,061 | 4,261 |
| Other assets | 338 | 338 |
| Total assets | $276,259 | $184,689 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's restricted cash?
- Alto Neuroscience (ANRO) reported restricted cash of $500K in Q1 2026.
- How has Alto Neuroscience's restricted cash changed year-over-year?
- Alto Neuroscience's restricted cash decreased by 0.0% year-over-year, from $500K to $500K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Alto Neuroscience's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude